Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0OBGHF
ADC Name
AbBJ-ConjE
Synonyms
AbBJ ConjE
   Click to Show/Hide
Organization
ADC Therapeutics SA; MedImmune LLC
Drug Status
Investigative
Indication
In total 1 Indication(s)
Chronic myeloid leukaemia [ICD11:2B33]
Investigative
Drug-to-Antibody Ratio
1.7
Antibody Name
Anti-CD22 mAb AbBJ
Antigen Name
B-cell receptor CD22 (CD22)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
AbBJ-ConjE linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
23
nM
CVCL_0004
Chronic myelogenous leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 23.00 nM Positive CD22 expression (CD22+++/++)
Method Description
Each ADC dilution was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.
In Vitro Model Chronic myelogenous leukemia K-562 cells CVCL_0004
References
Ref 1 Site-specific antibody-drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.